{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:13:12Z","timestamp":1793459592733,"version":"4.5.0"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. pediatr. gastroenterol. nutr."],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Linaclotide, a guanylate cyclase\u2010C agonist, was recently approved in the United States for treatment of children 6\u221217 years old with functional constipation (FC). This study evaluated the safety and efficacy of several linaclotide doses in children 6\u221217 years old with FC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this multicenter, randomized, double\u2010blind, placebo\u2010controlled phase 2 study, 173 children with FC\u00a0(based on Rome III criteria) were randomized to once\u2010daily linaclotide (A: 9 or 18\u2009\u03bcg, B: 18 or 36\u2009\u03bcg, or C: 36 or 72\u2009\u03bcg) or placebo in a 1:1:1:1 ratio for 6\u2010 to 11\u2010year\u2010olds (dosage determined by weight: 18 to &lt;35\u00a0or \u226535\u2009kg) and linaclotide (18, 36, 72, or 145\u2009\u03bcg) or placebo in a 1:1:1:1:1 ratio for 12\u2010 to 17\u2010year\u2010olds. The primary efficacy endpoint was change from baseline in weekly spontaneous bowel movement (SBM) frequency throughout the 4\u2010week treatment period. Adverse events (AE), clinical laboratory values, and electrocardiograms were monitored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Efficacy and safety were assessed in 173 patients (52.0% aged 6\u221211 years; 48.0% aged 12\u221217 years); 162 (93.6%) completed the treatment period. A numerical improvement in mean SBM\u00a0frequency was observed with increasing linaclotide doses (1.90 in 6\u2010 to 11\u2010year\u2010olds [36 or 72\u2009\u03bcg]\u00a0and 2.86 in 12\u2010 to 17\u2010year\u2010olds [72\u2009\u03bcg]). The most reported treatment\u2010emergent AE\u00a0was diarrhea, with most cases being mild; none were severe.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Linaclotide was well tolerated in this pediatric population, with a trend toward efficacy in the higher doses, warranting further evaluation.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jpn3.12184","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T09:10:17Z","timestamp":1711530617000},"page":"1059-1068","source":"Crossref","is-referenced-by-count":11,"title":["Randomized controlled trial of linaclotide in children aged 6\u221217 years with functional constipation"],"prefix":"10.1002","volume":"78","author":[{"given":"Carlo","family":"Di Lorenzo","sequence":"first","affiliation":[{"name":"Nationwide Children's Hospital Columbus Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Nurko","sequence":"additional","affiliation":[{"name":"Boston Children's Hospital Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Hyams","sequence":"additional","affiliation":[{"name":"Connecticut Children's Medical Center Hartford Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Rodriguez\u2010Araujo","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Almansa","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical Companies of Johnson and Johnson Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Shakhnovich","sequence":"additional","affiliation":[{"name":"Ironwood Pharmaceuticals,\u00a0Inc. Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Saps","sequence":"additional","affiliation":[{"name":"Miller School of Medicine University of Miami Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Pediatrics University of Kentucky Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.15171\/mejdd.2017.87"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10215087"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.015"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04273.x"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-1009"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e3181e67058"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-015-0142-4"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000000266"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-023-00563-0"},{"key":"e_1_2_9_11_1","unstructured":"US Food and Drug Administration.\u00a0Linzess\u00ae (linaclotide). Highlights of prescribing information. 2021."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010863"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.255"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.254"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.09.005"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.06.060"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003191"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000255"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.08.023"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04328.x"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i25.3425"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.04.005"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-021-00444-4"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134349"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.230"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90423-4"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003296"}],"container-title":["Journal of Pediatric Gastroenterology and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpn3.12184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T07:33:18Z","timestamp":1718350398000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jpn3.12184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1002\/jpn3.12184"],"URL":"https:\/\/doi.org\/10.1002\/jpn3.12184","archive":["Portico"],"relation":{},"ISSN":["0277-2116","1536-4801"],"issn-type":[{"value":"0277-2116","type":"print"},{"value":"1536-4801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,27]]}}}